A team led by Jeng-Rong Lin, Lakshay Kapil, Huan-An Tsai, Wen-Chieh Liao, Yu-Cheng Chou and senior author Chiung-Hui Liu of National Chung Hsing University and collaborating hospitals in Taiwan published the review in the journal Cancer Immunology, Immunotherapy on 24 September 2026. Their central argument is that two intertwined problems have held gamma-delta T cell therapies back: the intrinsic biological heterogeneity of the cells themselves, and the stress inflicted on them during laboratory manufacturing. By integrating recent advances in developmental biology, immune aging and cellular manufacturing, the authors propose a framework that could reshape how these therapies are designed, produced and deployed.

The first pillar of the review is developmental. Human gamma-delta T cells are not a single uniform entity but a layered family of subsets that emerge at different stages of life. Some lineages are seeded early in fetal development and persist for decades with tissue-homing and regulatory properties, while others are generated throughout life in response to infections and retain more pronounced inflammatory effector functions. This developmental layering means that the circulating gamma-delta T cell pool in a teenager looks fundamentally different from that of an eighty-year-old, not merely in proportion but in functional character. For a therapy that depends on harvesting, expanding and reinfusing a patient’s own cells, or on selecting donor cells for off-the-shelf products, that starting composition matters enormously.

To probe how aging reshapes these cells, the authors went beyond literature synthesis and re-analyzed publicly available single-cell RNA sequencing datasets of peripheral gamma-delta T cells from individuals spanning adolescence to old age. The analysis revealed an age-associated transcriptional remodeling program centered on mitochondrial dysfunction, oxidative stress and altered iron metabolism pathways. In practical terms, older donors’ gamma-delta T cells show molecular signatures consistent with reduced energy production capacity and heightened cellular stress, features that echo the broader phenomenon of immunosenescence. These findings suggest that donor age and cumulative immune history may directly influence the fitness of the cellular starting material used for adoptive therapies, a variable that most current clinical protocols do not systematically account for.

The second pillar of the review addresses what happens to these cells once they leave the body. Manufacturing gamma-delta T cell products typically requires ex vivo expansion, in which cells are stimulated with activating antibodies or bisphosphonate-based drugs and bathed in cytokine cocktails to drive them to multiply from millions to billions of copies. The review highlights a growing body of evidence that this process is far from benign. Repeated stimulation and prolonged culture push the cells toward terminal differentiation, exhaustion and senescence-like phenotypes. Cells that emerge from extended culture may look abundant under the microscope yet behave poorly once reinfused, showing shortened in vivo persistence, blunted cytotoxic activity and diminished capacity to home to tumors.

This manufacturing paradox helps explain a frustrating pattern in clinical data. Gamma-delta T cell therapies have consistently demonstrated strong safety profiles across numerous early-phase trials, with little of the cytokine release toxicity or graft-versus-host risk seen with other cell therapies. But objective response rates, especially in solid tumors, have lagged behind expectations. The review suggests that part of the answer lies in the product itself: infusions dominated by exhausted or senescent cells may simply lack the staying power and killing capacity needed to dent bulky, immunosuppressive tumors, no matter how impressive their performance in a laboratory dish.

Fortunately, the authors argue, the field is not short of potential solutions. They survey a range of emerging approaches aimed at preserving cellular fitness during manufacturing. Cytokine optimization involves tailoring the growth factors used in culture, favoring combinations that maintain a less-differentiated, more proliferative state rather than pushing cells toward terminal effector fates. Metabolic modulation seeks to bolster mitochondrial health and counteract oxidative stress, potentially through nutrient manipulation or pharmacological agents that support energy metabolism. Genetic engineering, including chimeric antigen receptor designs adapted for gamma-delta T cells, offers ways to enhance tumor recognition and resistance to the immunosuppressive tumor microenvironment.

Perhaps the most provocative strategy discussed is the use of senolytic interventions, drugs that selectively eliminate senescent cells. The review specifically references dasatinib, a tyrosine kinase inhibitor with known senolytic activity, as a candidate for purging dysfunctional cells from expanding cultures. By removing the senescent fraction during manufacturing, producers could in principle deliver products enriched for the most vigorous, persistent cells. The authors also emphasize that aging-informed donor selection, guided by the transcriptional markers their re-analysis uncovered, could help clinicians choose starting material with the greatest therapeutic potential, whether from young allogeneic donors or from patients whose own cells have aged more gracefully.

The review’s synthesis carries implications well beyond one cell type. It frames adoptive cell therapy not merely as a question of engineering smarter receptors but as a problem of cellular physiology, in which the biological age and stress history of the product determine clinical performance. As allogeneic, off-the-shelf gamma-delta T cell products move toward commercialization, understanding how developmental origin and donor age shape product quality could become a decisive competitive and scientific advantage. The authors call for integrating gamma-delta T cell developmental biology directly into manufacturing protocols, so that expansion conditions are designed around the biology of the specific subsets being grown rather than around one-size-fits-all stimulation recipes.

For patients with solid tumors, who still have limited options beyond surgery, radiation and checkpoint inhibitors, the promise of gamma-delta T cell therapy remains real but conditional. The Taiwanese team’s analysis makes clear that the path forward runs through the unglamorous details of cell culture: how long the cells are grown, what they are fed, how stressed they become, and how old they were to begin with. If the field can master those variables, the immune system’s most versatile tumor hunters may finally deliver on the expectations that two decades of research have built around them.

Subject of Research: Developmental biology and ex vivo manufacturing of human circulating gamma-delta T cells for adoptive cancer immunotherapy

Article Title: Revisiting human circulating γδ T cells: developmental insights and manufacturing challenges for cancer immunotherapy

Article References: Lin, J.-R., Kapil, L., Tsai, H.-A., Liao, W.-C., Chou, Y.-C., & Liu, C.-H. (2026). Revisiting human circulating γδ T cells: developmental insights and manufacturing challenges for cancer immunotherapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04561-2

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04561-2

Keywords: gamma-delta T cells, adoptive cell therapy, cancer immunotherapy, cellular senescence, immune aging, ex vivo expansion, single-cell RNA sequencing, CAR-gamma-delta T cells, mitochondrial dysfunction, senolytics, dasatinib, solid tumors